Period:
Draw Mode:
| Volume | 74,787 |
|
|||||
| News | - | ||||||
| Day High | 8.09 | Low High |
|||||
| Day Low | 7.87 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aadi Bioscience Inc | AADI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.16 | 2.03% | 8.06 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.01 | 7.87 | 8.09 | 8.06 | 7.90 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,173 | 74,787 | $ 8.00 | $ 598,086 | - | 6.80 - 17.27 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:40 | 46 | $ 8.40 | USD |
Aadi Bioscience Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 196.96M | 24.44M | 16.23M | $ 5.87M | $ -151.96k | -0.57 | -1,296.18 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 300.00k | 1.20% |
Aadi Bioscience News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AADI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.71 | 8.10 | 7.44 | 7.85 | 56,117 | 0.35 | 4.54% |
| 1 Month | 7.81 | 8.60 | 6.82 | 7.75 | 91,894 | 0.25 | 3.2% |
| 3 Months | 8.21 | 8.86 | 6.80 | 7.64 | 132,915 | -0.15 | -1.83% |
| 6 Months | 13.24 | 13.60 | 6.80 | 9.53 | 120,515 | -5.18 | -39.12% |
| 1 Year | 15.87 | 17.27 | 6.80 | 11.39 | 126,609 | -7.81 | -49.21% |
| 3 Years | 30.00 | 32.99 | 6.80 | 15.84 | 127,930 | -21.94 | -73.13% |
| 5 Years | 30.00 | 32.99 | 6.80 | 15.84 | 127,930 | -21.94 | -73.13% |
Aadi Bioscience Description
| Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. |